Способы и средства медикаментозной профилактики суицидов

Способы и средства медикаментозной профилактики суицидов

Автор: Козлов В.А., Голенков А.В., Булыгина И.Е.

Журнал: Суицидология @suicidology

Статья в выпуске: 2 (51) т.14, 2023 года.

Бесплатный доступ

Несмотря на то, что суициды потенциально предотвратимы, профилактика суицидов, смертность от которых сравнима со смертностью от бактериальных эпидемий, остаётся актуальной общемировой проблемой. ВОЗ описывает самоубийство как «акт преднамеренного убийства», который находится на крайнем конце непрерывного спектра суицидального поведения. Цель исследования - систематизация сведений о способах и средствах медикаментозной профилактики суицидов. Результаты. Рассмотрены вопросы профилактики суицидов. Авторы пришли к выводу о необходимости выявления предикторов суицидального поведения и формирования однородных групп населения: 1) психически больные (подгруппы - в определениях DSM-V); 2) относительно здоровые люди (те, кто не испытывает социального и экономического неблагополучия, клинически выраженных нарушений здоровья и кого нельзя квалифицировать в дефинициях DSM-V) - имеющих высокий риск совершения суицида в будущем, как имеющих постоянный паттерн предикторов суицидального поведения. Такая классификация позволит создать регистр лиц, склонных к совершению суицида и проводить плановую популяционную и клиническую профилактику совершения суицидов в целевых группах. В качестве средств профилактики суицидов рассмотрены методики ограничения доступа к смертоносным средствам и объектам, программы повышения осведомлённости о проблеме суицидов в школах. Особенно подробно проанализированы вопросы использования фармакологических средств с доказанным антисуицидальным эффектом: холекальциферолов, кетамина, клозапина, солей лития, внутривенных нейролептиков длительного действия, электросудорожной терапии. Исходя из рациональных сведений о биологической активности перечисленных фармакологических следует, что шизофреническое и депрессивное расстройства личности коморбидны суицидальности, но патогенетически с суицидальностью не связаны. Сделаны выводы, что для активной эффективной профилактики суицидов необходимо: 1) потенциальных суицидентов квалифицировать в однородные группы; 2) создать контролирующие структуры, в том числе, с применением цифровых вычислительных средств с целью создания регистра лиц, потенциально способных совершить суицид. В частности, таким средством могут быть технологии искусственного интеллекта и анализа больших данных для оперативного отслеживания триггерных запросов в сети интернет и с помощью средств мобильной связи.

Еще

Профилактика, суицид, кетамин, соли литий, клозапин, эбселен, холекальциферол, внутривенные нейролептики пролонгированного действия

Короткий адрес: https://sciup.org/140301922

IDR: 140301922   |   DOI: 10.32878/suiciderus.23-14-02(51)-36-58

Список литературы Способы и средства медикаментозной профилактики суицидов

  • Niculescu A.B., Le-Niculescu H., Levey D.F., Phalen P.L., Dainton H.L., Roseberry K., Niculescu E.M., Niezer J.O., Williams A., Graham D.L., Jones T.J., Venugopal V., Ballew A., Yard M., Gelbart T., Kurian S.M., Shekhar A., Schork N.J., Sandusky G.E., Salomon D.R. Precision medicine for suicidality: from universality to subtypes and personalization. Mol. Psychiatry. 2017; 22 (9): 1250-1273. DOI: 10.1038/mp.2017.128
  • Bachmann S. Epidemiology of suicide and the psychiatric perspective. Int. J. Environ. Res. Public Health. 2018; 15(7): 1425. DOI: 10.3390/ijerph15071425
  • De Berardis D., Vellante F., Pettorruso M., Lucidi L., Tambelli A., Di Muzio I., Gianfelice G., Ventriglio A., Fornaro M., Serafini G., Pompili M., Perna G., Fraticelli S., Martinotti G., di Giannantonio M. Suicide and genetic biomarkers: toward personalized tailored-treatment with lithium and clozapine. Curr Pharm Des. 2021; 27 (30): 3293-3304. DOI: 10.2174/1381612827666210603143353
  • Козлов В.А., Голенков А.В., Сапожников С.П. Роль генома в суицидальном поведении (обзор литературы). Суицидология. 2021; 12 (1): 3-22. [Kozlov V.A., Golenkov A.V., Sapozhnikov S.P. The role of the genome in suicidal behavior (literature review). Suicidology / Suicidologiya. 2021; 12 (1): 3-22.] (In Russ / Engl) DOI: 10.32878/suiciderus.21-12-01(42)-3-22
  • Griffin L., Hosking W., Gill P.R., Shearson K., Ivey G., Sharples J. The gender paradox: understanding the role of masculinity in suicidal ideation. Am J Mens Health. 2022 Sep-Oct; 16 (5): 15579883221123853. DOI: 10.1177/15579883221123853
  • van Heeringen K., Mann J.J. The neurobiology of suicide. Lancet Psychiatry. 2014 Jun; 1 (1): 63-72. DOI: 10.1016/S2215-0366(14)70220-2
  • Ernst C., Mechawar N., Turecki G. Suicide neurobiology. Prog Neurobiol. 2009 Dec; 89 (4): 315-333. DOI: 10.1016/j.pneurobio.2009.09.001
  • Sobanski T., Peikert G., Kastner U.W., Wagner G. Suicidal behavior-advances in clinical and neurobiological researchand improvement of prevention strategies. World J Psychiatry. 2022 Sep 19; 12 (9): 1115-1126. DOI: 10.5498/wjp.v12.i9.1115
  • Zalsman G., Hawton K., Wasserman D., van Heeringen K., Arensman E., Sarchiapone M., Carli V., Höschl C., Barzilay R., Balazs J., Purebl G., Kahn J.P., Sáiz P.A., Lipsicas C.B., Bobes J., Cozman D., Hegerl U., Zohar J. Suicide prevention strategies revisited: 10-year systematic review. Lancet Psychiatry. 2016 Jul; 3 (7): 646-659. DOI: 10.1016/S2215-0366(16)30030-X
  • Hawkins E.M., Coryell W., Leung S., Parikh S.V., Weston C., Nestadt P., Nurnberger J.I.Jr., Kaplin A., Kumar A., Farooqui A.A., El-Mallakh R.S. National network of depression centers suicide prevention task group. Effects of somatic treatments on suicidal ideation and completed suicides. Brain Behav. 2021; 11 (11): e2381. DOI: 10.1002/brb3.2381
  • Girgis R.R. The neurobiology of suicide in psychosis: A systematic review. J Psychopharmacol. 2020; 34 (8): 811-819. DOI: 10.1177/0269881120936919
  • Limosin F., Loze J.Y., Philippe A., Casadebaig F., Rouillon F. Ten-year prospective follow-up study of the mortality by suicide in schizophrenic patients. Schizophr Res. 2007; 94 (1-3): 23-28. DOI: 10.1016/j.schres.2007.04.031
  • Pompili M., Orsolini L., Lamis D.A., Goldsmith D.R., Nardella A., Falcone G., Corigliano V., Luciano M., Fiorillo A. Suicide Prevention IN SCHIZOPHRENIA: DO Long-Acting Injectable Antipsychotics (LAIs) have a role? CNS Neurol Disord Drug Targets. 2017; 16 (4): 454-462. DOI: 10.2174/1871527316666170223163629
  • Madsen T., Karstoft K.I., Secher R.G., Austin S.F., Nordentoft M. Trajectories of suicidal ideation in patients with first-episode psychosis: secondary analysis of data from the OPUS trial. Lancet Psychiatry. 2016; 3 (5): 443-450. DOI: 10.1016/S2215-0366(15)00518-0
  • Fuller-Thomson E., Hollister B. Schizophrenia and suicide attempts: findings from a representative community-based Canadian SAMPle. Schizophr Res Treatment. 2016: 3165243. DOI: 10.1155/2016/3165243
  • Huang C.Y., Fang S.C., Shao Y.J. Comparison of longacting injectable antipsychotics with oral antipsychotics and suicide and all-cause mortality in patients with newly diagnosed schizophrenia. JAMA Netw Open. 2021; 4 (5): e218810. DOI: 10.1001/jamanetworkopen.2021.8810. Erratum in: JAMA Netw Open. 2022; 5 (4): e2210829.
  • Wasserman D., Rihmer Z., Rujescu D., Sarchiapone M., Sokolowski M., Titelman D., Zalsman G., Zemishlany Z., Carli V. Az Európai Pszichiátriai Szövetség (European Psychiatric Association, EPA) úmutatója az öngyilkosság kezelésére és megelözésére [The European Psychiatric Association (EPA) guidance on suicide treatment and prevention]. Neuropsychopharmacol Hung. 2012; 14 (2): 113-136. (In Hungarian)
  • Mars B., Heron J., Klonsky E.D., Moran P., O'Connor R.C., Tilling K., Wilkinson P., Gunnell D. Predictors of future suicide attempt among adolescents with suicidal thoughts or non-suicidal self-harm: a population-based birth cohort study. Lancet Psychiatry. 2019 Apr; 6 (4): 327-337. DOI: 10.1016/S2215-0366(19)30030-6
  • Зотов П.Б., Уманский С.М., Уманский М.С. Необходимость и сложности суицидологического учета. Академический журнал Западной Сибири. 2010; 4: 48. [Zotov P.B., Umansky S.M., Umansky M.S. Necessity and difficulties of suicidological accounting. Academic Journal of West Siberia / Akademicheskiĭ zhurnal Zapadnoĭ Sibiri. 2010; 4: 48.] (In Russ)
  • Суицидальные и несуицидальные самоповреждения подростков / Коллективная монография. Под редакцией проф. П.Б. Зотова. Тюмень: Вектор Бук, 2021. 472 с. ISBN 978-5-91409-537-3 [Suicidal and non-suicidal selfharm of adolescents / Collective monograph. Edited by Prof. P.B. Zotov. Tyumen: Vector Book, 2021. 472 p. ISBN 978-5-91409-537-3] (In Russ)
  • Miller J.N., Black D.W. Bipolar disorder and suicide: a review. Curr Psychiatry Rep. 2020; 22 (2): 6. DOI: 10.1007/s11920-020-1130-0
  • Turecki G., Brent D.A., Gunnell D., O'Connor R.C., Oquendo M.A., Pirkis J., Stanley B.H. Suicide and suicide risk. Nat Rev Dis Primers. 2019; 5 (1): 74. DOI: 10.1038/s41572-019-0121-0
  • Mann J.J., Michel C.A., Auerbach R.P. Improving suicide prevention through evidence-based strategies: a systematic review. Am J Psychiatry. 2021; 178 (7): 611-624. DOI: 10.1176/appi.ajp.2020.20060864
  • Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000; 47 (4): 351-354. DOI: 10.1016/s0006-3223(99)00230-9
  • McIntyre R.S., Carvalho I.P., Lui L.M.W., Majeed A., Masand P.S., Gill H., Rodrigues N.B., Lipsitz O., Coles A.C., Lee Y., Tamura J.K., Iacobucci M., Phan L., Nasri F., Singhal N., Wong E.R., Subramaniapillai M., Mansur R., Ho R., Lam R.W., Rosenblat J.D. The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. J Affect Disord. 2020; 276: 576-584. DOI: 10.1016/j.jad.2020.06.050
  • Hochschild A., Grunebaum M.F., Mann J.J. The rapid anti-suicidal ideation effect of ketamine: A systematic review. Prev Med. 2021; 152 (Pt 1): 106524. DOI: 10.1016/j.ypmed.2021.106524
  • Xiong J., Lipsitz O., Chen-Li D., Rosenblat J.D., Rodrigues N.B., Carvalho I., Lui L.M.W., Gill H., Narsi F., Mansur R.B., Lee Y., McIntyre R.S. The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. J Psychiatr Res. 2021; 134: 57-68. DOI: 10.1016/j.jpsychires.2020.12.038
  • Zanos P., Gould T.D. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018; 23 (4): 801-811. DOI: 10.1038/mp.2017.255.
  • Bartoli F., Riboldi I., Crocamo C., Di Brita C., Clerici M., Carrà G. Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis. Neurosci Biobehav Rev. 2017; 77: 232-236. DOI: 10.1016/j.neubiorev.2017.03.010
  • Lapidus K.A., Levitch C.F., Perez A.M., Brallier J.W., Parides M.K., Soleimani L., Feder A., Iosifescu D.V., Charney D.S., Murrough J.W. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014; 76 (12): 970-976. DOI: 10.1016/j.biopsych.2014.03.026
  • Price R.B., Iosifescu D.V., Murrough J.W., Chang L.C., Al Jurdi R.K., Iqbal S.Z., Soleimani L., Charney D.S., Foulkes A.L., Mathew S.J. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014; 31 (4): 335-343. DOI: 10.1002/da.22253
  • Grunebaum M.F., Galfalvy H.C., Choo T.H., Keilp J.G., Moitra V.K., Parris M.S., Marver J.E., Burke A.K., Milak M.S., Sublette M.E., Oquendo M.A., Mann J.J. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018; 175 (4): 327-335. DOI: 10.1176/appi.ajp.2017.17060647
  • Wilkinson S.T., Ballard E.D., Bloch M.H., Mathew S.J., Murrough J.W., Feder A., Sos P., Wang G., Zarate C.A.Jr., Sanacora G. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018; 175 (2): 150-158. DOI: 10.1176/appi.ajp.2017.17040472
  • Fava M., Freeman M.P., Flynn M., Judge H., Hoeppner B.B., Cusin C., Ionescu D.F., Mathew S.J., Chang L.C., Iosifescu D.V., Murrough J., Debattista C., Schatzberg A.F., Trivedi M.H., Jha M.K., Sanacora G., Wilkinson S.T., Papakostas G.I. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020; 25 (7): 1592-1603. DOI: 10.1038/s41380-018-0256-5
  • Murrough J.W., Iosifescu D.V., Chang L.C., Al Jurdi R.K., Green C.E., Perez A.M., Iqbal S., Pillemer S., Foulkes A., Shah A., Charney D.S., Mathew S.J. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013; 170 (10): 1134-1142. DOI: 10.1176/appi.ajp.2013.13030392
  • Murrough J.W., Perez A.M., Pillemer S., Stern J., Parides M.K., aan het Rot M., Collins K.A., Mathew S.J., Charney D.S., Iosifescu D.V. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatmentresistant major depression. Biol Psychiatry. 2013; 74 (4): 250-256. DOI: 10.1016/j.biopsych.2012.06.022
  • Lengvenyte A., Olié E., Courtet P. Suicide has many faces, so does ketamine: a narrative review on ketamine's antisuicidal actions. Curr Psychiatry Rep. 2019; 21 (12): 132. DOI: 10.1007/s11920-019-1108-y
  • Singh J.B., Fedgchin M., Daly E., Xi L., Melman C., De Bruecker G., Tadic A., Sienaert P., Wiegand F., Manji H., Drevets W.C., Van Nueten L. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2016; 80 (6): 424-431. DOI: 10.1016/j.biopsych.2015.10.018
  • Zanos P., Gould T.D. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018; 23 (4): 801-811. DOI: 10.1038/mp.2017.255
  • Dean R.L., Marquardt T., Hurducas C., Spyridi S., Barnes A., Smith R., Cowen P.J., McShane R., Hawton K., Malhi G.S., Geddes J., Cipriani A. Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. Cochrane Database Syst Rev. 2021; 10 (10): CD011611. DOI: 10.1002/14651858.CD011611.pub3
  • Stahl S.M. Mechanism of action of ketamine. CNS Spectr. 2013; 18 (4): 171-174. DOI: 10.1017/S109285291300045X
  • Menon V., Varadharajan N., Faheem A., Andrade C. ketamine vs electroconvulsive therapy for major depressive episode: a systematic review and meta-analysis. JAMA Psychiatry. 2023: e230562. DOI: 10.1001/jamapsychiatry.2023.0562 43. Rhee T.G., Shim S.R., Forester B.P., Nierenberg A.A.,
  • McIntyre R.S., Papakostas G.I., Krystal J.H., Sanacora G., Wilkinson S.T. efficacy and safety of ketamine vs electroconvulsive therapy among patients with major depressive episode: a systematic review and meta-analysis. JAMA Psychiatry. 2022; 79 (12): 1162-1172. DOI: 10.1001/jamapsychiatry.2022.3352
  • Meltzer H.Y., Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry. 1995; 152 (2): 183-190. DOI: 10.1176/ajp.152.2.183
  • Masdrakis V.G., Baldwin D.S. Prevention of suicide by clozapine in mental disorders: systematic review. Eur Neuropsychopharmacol. 2023; 69: 4-23. DOI: 10.1016/j.euroneuro.2022.12.011
  • Zalsman G., Hawton K., Wasserman D., van Heeringen K., Arensman E., Sarchiapone M., Carli V., Höschl C., Barzilay R., Balazs J., Purebl G., Kahn J.P., Sáiz P.A., Lipsicas C.B., Bobes J., Cozman D., Hegerl U., Zohar J. Suicide prevention strategies revisited: 10-year systematic review. Lancet Psychiatry. 2016; 3 (7): 646-659. DOI: 10.1016/S2215-0366(16)30030-X
  • Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., Bourgeois M., Chouinard G., Islam M.Z., Kane J., Krishnan R., Lindenmayer J.P., Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). International Suicide Prevention Trial Study Group. Arch Gen Psychiatry. 2003; 60 (1): 82-91. DOI: 10.1001/archpsyc.60.1.82
  • Glick I.D., Zaninelli R., Hsu C., Young F.K., Weiss L., Gunay I., Kumar V. Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior. J Clin Psychiatry. 2004; 65 (5): 679-685. DOI: 10.4088/jcp.v65n0513
  • Bastiampillai T., Tonnu O., Tibrewal P., Dhillon R. Why not clozapine for the patient with schizophrenia at risk of suicide? Asian J Psychiatr. 2017; 26: 6-7. DOI: 10.1016/j.ajp.2016.12.008
  • De Berardis D., Vellante F., Pettorruso M., Lucidi L., Tambelli A., Di Muzio I., Gianfelice G., Ventriglio A., Fornaro M., Serafini G., Pompili M., Perna G., Fraticelli S., Martinotti G., di Giannantonio M. Suicide and Genetic Biomarkers: Toward Personalized Tailored-treatmentwith Lithium and Clozapine. Curr Pharm Des. 2021; 27 (30): 3293-3304. DOI: 10.2174/1381612827666210603143353
  • Taipale H., Mittendorfer-Rutz E., Alexanderson K., Majak M., Mehtälä J., Hoti F., Jedenius E., Enkusson D., Leval A., Sermon J., Tanskanen A., Tiihonen J. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018; 197: 274-280. DOI: 10.1016/j.schres.2017.12.010
  • Tariq M.M., Streeten E.A., Smith H.A., Sleemi A., Khabazghazvini B., Vaswani D., Postolache T.T. Vitamin D: a potential role in reducing suicide risk? Int J Adolesc Med Health. 2011; 23 (3): 157-165. DOI: 10.1515/ijamh.2011.038
  • Fond G., Faugere M., Faget-Agius C., Cermolacce M., Richieri R., Boyer L., Lançon C. Hypovitaminosis D is associated with negative symptoms, suicide risk, agoraphobia, impaired functional remission, and antidepressant consumption in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2019; 269 (8): 879-886. DOI: 10.1007/s00406-018-0932-0
  • Menon V., Kar S.K., Suthar N., Nebhinani N. Vitamin D and Depression: A Critical Appraisal of the Evidence and Future Directions. Indian J Psychol Med. 2020; 42 (1): 11-21. DOI: 10.4103/IJPSYM.IJPSYM_160_19
  • Office of dietary supplements NIoH. Vitamin D fact sheet for health professionals. National Institutes of Health. https: //ods.od.nih.gov/factsheets/VitaminDHealthProfessional/?print=1. Updated August 17, 2021. Accessed February 25, 2022.
  • Gokalp G. The association between low vitamin D levels and suicide attempts in adolescents. Ann Clin Psychiatry. 2020; 32 (2): 106-113.
  • Kim S.Y., Jeon S.W., Lim W.J., Oh K.S., Shin D.W., Cho S.J., Park J.H., Kim Y.H., Shin Y.C. Vitamin D deficiency and suicidal ideation: A cross-sectional study of 157,211 healthy adults. J Psychosom Res. 2020; 134: 110125. DOI: 10.1016/j.jpsychores.2020.110125
  • Lavigne J.E., Gibbons J.B. The association between vitamin D serum levels, supplementation, and suicide attempts and intentional self-harm. PLoS One. 2023; 18 (2): e0279166. DOI: 10.1371/journal.pone.0279166
  • Wei Y.X., Liu B.P., Qiu H.M., Zhang J.Y., Wang X.T., Jia C.X. Effects of vitamin D-related gene polymorphisms on attempted suicide. Psychiatr Genet. 2021; 31 (6): 230-238. DOI: 10.1097/YPG.0000000000000295
  • Hawkins E.M., Coryell W., Leung S., Parikh S.V., Weston C., Nestadt P., Nurnberger J.I.Jr., Kaplin A., Kumar A., Farooqui A.A., El-Mallakh R.S. National network of depression centers suicide prevention task group. Effects of somatic treatments on suicidal ideation and completed suicides. Brain Behav. 2021; 11 (11): e2381. DOI: 10.1002/brb3.2381
  • Benard V., Vaiva G., Masson M., Geoffroy P.A. Lithium and suicide prevention in bipolar disorder. Encephale. 2016; 42 (3): 234-241. DOI: 10.1016/j.encep.2016.02.006
  • Young W. Review of lithium effects on brain and blood. Cell Transplant. 2009; 18 (9): 951-975. DOI: 10.3727/096368909X471251
  • Del Matto L., Muscas M., Murru A., Verdolini N., Anmella G., Fico G., Corponi F., Carvalho A.F., Samalin L., Carpiniello B., Fagiolini A., Vieta E., Pacchiarotti I. Lithium and suicide prevention in mood disorders and in the general population: A systematic review. Neurosci Biobehav Rev. 2020; 116: 142-153. DOI: 10.1016/j.neubiorev.2020.06.017
  • Cipriani A., Hawton K., Stockton S., Geddes J.R. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013; 346: f3646. DOI: 10.1136/bmj.f3646
  • Nabi Z., Stansfeld J., Plöderl M., Wood L., Moncrieff J. Effects of lithium on suicide and suicidal behaviour: a systematic review and meta-analysis of randomised trials. Epidemiol Psychiatr Sci. 2022; 31: e65. DOI: 10.1017/S204579602200049X
  • Abou-Saleh M.T., Müller-Oerlinghausen B., Coppen A.J. Lithium in the episode and suicide prophylaxis and in augmenting strategies in patients with unipolar depression. Int J Bipolar Disord. 2017; 5 (1): 11. DOI: 10.1186/s40345-017-0080-x
  • Smith E.G., Austin K.L., Kim H.M., Miller D.R., Sauer B.C., Valenstein M. Suicide death over the first year of lithium versus valproate treatment in cohorts with and without bipolar disorder. J Psychiatr Res. 2022; 147: 349-356. DOI: 10.1016/j.jpsychires.2021.12.011
  • Kanehisa M., Terao T., Shiotsuki I., Kurosawa K., Takenaka R., Sakamoto T., Shigemitsu O., Ishii N., Hatano K., Hirakawa H. Serum lithium levels and suicide attempts: a case-controlled comparison in lithium therapynaive individuals. Psychopharmacology (Berl). 2017; 234 (22): 3335-3342. DOI: 10.1007/s00213-017-4729-z
  • Kugimiya T., Ishii N., Kohno K., Kanehisa M., Hatano K., Hirakawa H., Terao T. Lithium in drinking water and suicide prevention: The largest nationwide epidemiological study from Japan. Bipolar Disord. 2021; 23 (1): 33-40. DOI: 10.1111/bdi.12983
  • Ando S., Suzuki H., Matsukawa T., Usami S., Muramatsu H., Fukunaga T., Yokoyama K., Okazaki Y., Nishida A. Comparison of lithium levels between suicide and nonsuicide fatalities: Cross-sectional study. Transl Psychiatry. 2022; 12 (1): 466. DOI: 10.1038/s41398-022-02238-9. Erratum in: Transl Psychiatry. 2023 Feb 13; 13(1): 52
  • Benard V., Vaiva G., Masson M., Geoffroy P.A. Lithium and suicide prevention in bipolar disorder. Encephale. 2016; 42 (3): 234-241. (In French) DOI: 10.1016/j.encep.2016.02.006
  • Jope R.S. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci. 2011; 4:
  • DOI: 10.3389/fnmol.2011.00016 73. Ramli F.F., Cowen P.J., Godlewska B.R. The Potential
  • Use of Ebselen in Treatment-Resistant Depression. Pharmaceuticals (Basel). 2022; 15 (4): 485. DOI: 10.3390/ph15040485
  • University of Oxford and sound pharmaceuticals complete phase 2 bipolar disorder study with SPI-1005 https: // soundpharma.com/university-of-oxford-and-soundpharmaceuticals-complete-phase-2-bipolar-disorder-studywith-spi-1005
  • Abuhammad A., Laurieri N., Rice A., Lowe E.D., Singh N., Naser S.M., Ratrout S.S., Churchill G.C. Structural and biochemical analysis of human inositol monophosphatase-1 inhibition by ebselen. J Biomol Struct Dyn. 2023: 1-13. DOI: 10.1080/07391102.2023.2176925
  • Martini F., Bruning C.A., Soares S.M., Nogueira C.W., Zeni G. Inhibitory effect of ebselen on cerebral acetylcholinesterase activity in vitro: kinetics and reversibility of inhibition. Curr Pharm Des. 2015; 21 (7): 920-924. DOI: 10.2174/1381612820666141014124319
  • Xie Y., Tan Y., Zheng Y., Du X., Liu Q. Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice. J Biol Inorg Chem. 2017; 22 (6): 851-865. DOI: 10.1007/s00775-017-1463-2
  • Barkus C., Ferland J.N., Adams W.K., Churchill G.C., Cowen P.J., Bannerman D.M., Rogers R.D., Winstanley C.A., Sharp T. The putative lithium-mimetic ebselen reduces impulsivity in rodent models. J Psychopharmacol. 2018; 32 (9): 1018-1026. DOI: 10.1177/0269881118784876
  • Masaki C., Sharpley A.L., Cooper C.M., Godlewska B.R., Singh N., Vasudevan S.R., Harmer C.J., Churchill G.C., Sharp T., Rogers R.D., Cowen P.J. Effects of the potential lithium-mimetic, ebselen, on impulsivity and emotional processing. Psychopharmacology (Berl). 2016; 233 (14): 2655-2661. DOI: 10.1007/s00213-016-4319-5
  • Al-Daghri N.M., Al-Saleh Y., Aljohani N., Sulimani R., Al-Othman A.M., Alfawaz H., Fouda M., Al-Amri F., Shahrani A., Alharbi M., Alshahrani F., Tamimi W., Sabico S., Rizzoli R., Reginster J.Y. Vitamin D status correction in Saudi Arabia: an experts' consensus under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO). Arch Osteoporos. 2017; 12 (1): 1. DOI: 10.1007/s11657-016-0295-y
  • Harvey N.C., Biver E., Kaufman J.M., Bauer J., Branco J., Brandi M.L., Bruyère O., Coxam V., Cruz-Jentoft A., Czerwinski E., Dimai H., Fardellone P., Landi F., Reginster J.Y., Dawson-Hughes B., Kanis J.A., Rizzoli R., Cooper C. The role of calcium supplementation in healthy musculoskeletal ageing: An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporos Int. 2017; 28 (2): 447-462. DOI: 10.1007/s00198-016-3773-6
  • Chevalley T., Brandi M.L., Cashman K.D., Cavalier E., Harvey N.C., Maggi S., Cooper C., Al-Daghri N., Bock O., Bruyère O., Rosa M.M., Cortet B., Cruz-Jentoft A.J., Cherubini A., Dawson-Hughes B., Fielding R., Fuggle N., Halbout P., Kanis J.A., Kaufman J.M., Lamy O., Laslop A., Yerro M.C.P., Radermecker R., Thiyagarajan J.A., Thomas T., Veronese N., de Wit M., Reginster J.Y., Rizzoli R. Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group. Aging Clin Exp Res. 2022; 34 (11): 2603-2623. DOI: 10.1007/s40520-022-02279-6
  • Marcinkowska E., Wallace G.R., Brown G. The Use of 1α,25-Dihydroxyvitamin D₃ as an anticancer agent. Int J Mol Sci. 2016; 17 (5): 729. DOI: 10.3390/ijms17050729
  • Estébanez N., Gómez-Acebo I., Palazuelos C., Llorca J., Dierssen-Sotos T. Vitamin D exposure and risk of breast cancer: a meta-analysis. Sci Rep. 2018; 8 (1): 9039. DOI: 10.1038/s41598-018-27297-1
  • Carlberg C., Muñoz A. An update on vitamin D signaling and cancer. Semin Cancer Biol. 2022; 79: 217-230. DOI: 10.1016/j.semcancer.2020.05.018
  • Lawler T., Warren Andersen S. Serum 25-Hydroxyvitamin D and cancer risk: a systematic review of mendelian randomization studies. Nutrients. 2023; 15 (2): 422. DOI: 10.3390/nu15020422
  • Rosenberg A.R., Tabacchi M., Ngo K.H., Wallendorf M., Rosman I.S., Cornelius L.A., Demehri S. Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. JCI Insight. 2019; 4 (6): e125476. DOI: 10.1172/jci.insight.125476
  • Holick M.F. Shedding new light on the role of the sunshine vitamin D for skin health: the lncRNA-skin cancer connection. Exp Dermatol. 2014; 23 (6): 391-392. DOI: 10.1111/exd.12386
  • Chen J., van der Duin D., Campos-Obando N., Ikram M.A., Nijsten T.E.C., Uitterlinden A.G., Zillikens M.C. Serum 25-hydroxyvitamin D3 is associated with advanced glycation end products (AGEs) measured as skin autofluorescence: The Rotterdam Study. Eur J Epidemiol. 2019; 34 (1): 67-77. DOI: 10.1007/s10654-018-0444-2
  • Туйзарова И.А., Свеклина Т.С., Козлов В.А., Сардинов Р.Т. Роль кальция и витамина D в формировании артериальной гипертензии. Патологическая физиология и экспериментальная терапия. 2020; 64 (2): 117-123. [Tuizarova IA, Sveklina TS, Kozlov VA, Sardinov RT. The role of calcium and vitamin D in the formation of arterial hypertension. Pathological physiology and experimental therapy. 2020; 64 (2): 117-123.] (In Russ)
  • Ceolin G., Matsuo L.H., Confortin S.C., D'Orsi E., Rieger D.K., Moreira J.D. Lower serum 25-hydroxycholecalciferol is associated with depressive symptoms in older adults in Southern Brazil. Nutr J. 2020; 19 (1): 123. DOI: 10.1186/s12937-020-00638-5
  • Łukawska E., Frankiewicz D., Izak M., Woźniak A., Dworacki G., Niemir Z.I. Lithium toxicity and the kidney with special focus on nephrotic syndrome associated with the acute kidney injury: A case-based systematic analysis. J Appl Toxicol. 2021; 41 (12): 1896-1909. DOI: 10.1002/jat.4167
Еще
Статья научная
SciUp 2024 © 2024 ©